Published in Breast Cancer Res on November 13, 2008
Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol (2009) 3.35
Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol (2011) 3.33
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
GOBO: gene expression-based outcome for breast cancer online. PLoS One (2011) 2.81
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res (2012) 2.11
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res (2010) 1.94
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67
Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One (2011) 1.56
The influence of feature selection methods on accuracy, stability and interpretability of molecular signatures. PLoS One (2011) 1.46
Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. BMC Bioinformatics (2010) 1.33
Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer (2010) 1.22
ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol (2012) 1.16
The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One (2011) 1.14
Combining gene signatures improves prediction of breast cancer survival. PLoS One (2011) 1.11
A critical evaluation of network and pathway-based classifiers for outcome prediction in breast cancer. PLoS One (2012) 1.06
Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res (2010) 1.05
Can survival prediction be improved by merging gene expression data sets? PLoS One (2009) 1.04
Role of RBM25/LUC7L3 in abnormal cardiac sodium channel splicing regulation in human heart failure. Circulation (2011) 1.04
A novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancer. PLoS Comput Biol (2014) 1.01
Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? PLoS One (2011) 0.98
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer (2012) 0.97
Comparison of data-merging methods with SVM attribute selection and classification in breast cancer gene expression. BMC Bioinformatics (2012) 0.93
Integration of clinical and gene expression data has a synergetic effect on predicting breast cancer outcome. PLoS One (2012) 0.93
The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res (2012) 0.91
Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome Med (2010) 0.89
External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement. PLoS One (2011) 0.89
Impact of collection and storage of lung tumor tissue on whole genome expression profiling. J Mol Diagn (2012) 0.88
Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures. PLoS One (2012) 0.87
Annotation enrichment analysis: an alternative method for evaluating the functional properties of gene sets. Sci Rep (2014) 0.87
Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer. PLoS One (2009) 0.86
Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. Cancer Res (2014) 0.86
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. BMC Cancer (2014) 0.85
A comprehensive sensitivity analysis of microarray breast cancer classification under feature variability. BMC Bioinformatics (2009) 0.84
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis. Br J Cancer (2009) 0.84
Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. OMICS (2011) 0.83
A signature inferred from Drosophila mitotic genes predicts survival of breast cancer patients. PLoS One (2011) 0.83
Expression profiling of cervical cancers in Indian women at different stages to identify gene signatures during progression of the disease. Cancer Med (2013) 0.83
An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. BMC Med Genomics (2012) 0.83
Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis. PLoS One (2015) 0.82
A comparative analysis of biomarker selection techniques. Biomed Res Int (2013) 0.82
Empirical Bayes estimation of posterior probabilities of enrichment: a comparative study of five estimators of the local false discovery rate. BMC Bioinformatics (2013) 0.81
Network analysis of gene lists for finding reproducible prognostic breast cancer gene signatures. Bioinformation (2012) 0.79
The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation. PLoS Genet (2013) 0.79
Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer. PLoS One (2014) 0.77
Prognostic signatures in breast cancer: correlation does not imply causation. Breast Cancer Res (2012) 0.76
Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients. BMC Clin Pathol (2015) 0.75
The influence of cancer tissue sampling on the identification of cancer characteristics. Sci Rep (2015) 0.75
Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia (2015) 0.75
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl (2013) 0.75
Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach. Genetics (2016) 0.75
Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application. PLoS One (2016) 0.75
The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms. Sci Rep (2017) 0.75
Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer. PLoS One (2017) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet (2006) 7.16
Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A (2006) 6.26
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol (2001) 6.23
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer (2007) 4.74
Aberrant and alternative splicing in cancer. Cancer Res (2004) 4.67
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Common markers of proliferation. Nat Rev Cancer (2006) 3.85
Molecular portraits and the family tree of cancer. Nat Genet (2002) 3.28
Unbalanced alternative splicing and its significance in cancer. Bioessays (2006) 3.17
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol (2007) 2.46
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat (2008) 1.96
The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol (2006) 1.95
Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer (2007) 1.94
Predictive accuracy and explained variation in Cox regression. Biometrics (2000) 1.86
Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res (2006) 1.83
Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist (2007) 1.78
A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet (1998) 1.77
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer (2007) 1.75
Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res (2007) 1.73
Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer (2007) 1.70
Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics (2008) 1.45
Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res (2006) 1.34
Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res (2006) 1.29
Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon. Oncogene (2006) 1.16
A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. Oncogene (2005) 0.91
Estimation of predictive accuracy in survival analysis using R and S-PLUS. Comput Methods Programs Biomed (2007) 0.81
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol (2011) 5.72
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet (2011) 5.62
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res (2007) 4.41
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol (2008) 4.13
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer (2007) 4.06
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet (2006) 3.96
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med (2011) 3.68
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
p300/CBP and cancer. Oncogene (2004) 3.13
An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet (2005) 3.04
MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res (2011) 3.02
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A (2009) 2.99
Haemolysis during sample preparation alters microRNA content of plasma. PLoS One (2011) 2.92
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet (2005) 2.70
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 2.64
Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics (2010) 2.34
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
An evaluation of analysis pipelines for DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Epigenetics (2013) 2.28
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res (2014) 2.25
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
ChAMP: 450k Chip Analysis Methylation Pipeline. Bioinformatics (2013) 2.21
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res (2012) 2.18
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Chromatin position effects assayed by thousands of reporters integrated in parallel. Cell (2013) 2.16
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics (2006) 2.12
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer (2008) 2.11
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06
A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene (2005) 2.05
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
[Categorization of occult tumour cells in lymph nodes in patients with colon cancer not reliable enough]. Ned Tijdschr Geneeskd (2011) 2.03
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol (2010) 2.01